Gastrointestinal Drugs Market Share Analysis, Growth Opportunity, Industry Size, Top Key Players, Regional Demand Overview, Trends and Outlook 2023

Gastrointestinal Drugs Market Share Analysis, Growth Opportunity, Industry Size, Top Key Players, Regional Demand Overview, Trends and Outlook 2023

“Gastrointestinal Drugs Market”
Gastrointestinal Drugs Market Analysis By Drug Class (Acid Neutralizers, Laxatives & Antidiarrheal, Anti-Emetics, Antiulcer), By Type Of Disease (Esophagus Diseases, Stomach Diseases, Intestinal Diseases, Rectum Diseases) – Asia Pacific Industry Forecast till 2023

Asia Pacific Gastrointestinal Drugs Market Share Is Expected to Grow at a CAGR of 6.1% During The Forecast Period 2017-2023.

Market Overview

Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, esophagus, liver, gallbladder, and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation, and many more. The diseases of gastrointestinal have become common in the people across world.  Gastrointestinal diseases are caused by various reasons such as acid reflux, heartburn, indigestion, nausea and vomiting, peptic ulcer disease, abdominal pain syndrome, biliary tract disorders, gallbladder disorders, and gallstone pancreatitis.

Avail a Free Sample PDF@ https://www.marketresearchfuture.com/sample_request/633

Key Findings

  • The Asia gastrointestinal drugs market is expected to reach USD 20,772.4 million by 2023 at a CAGR of 6.1%
  • Acid neutralizers segment accounted for the largest market share with 33.3% of the Asia gastrointestinal drug market, by drug types in 2016
  • In 2016, Esophagus diseases segment accounted for the major share of the market as it was the most widely occurring GI disease. The Asia esophagus diseases market by type of diseases is expected to reach USD 7,427.6 million by 2023, growing at a CAGR of 6.32% from 2017 to 2023
  • India is expected to be the fastest growing market at a CAGR of 6.60% during the forecast period

Some of the leading key players in this market are listed below-

Abbott

Allergan Plc

AstraZeneca

Eli lilly Company

F. Hoffmann-La Roche Ltd

GlaxoSmithKline plc

Pfizer Inc

Valeant Pharmaceuticals

and others.

Gastrointestinal Drugs Market Segmentation:

The gastrointestinal drugs market is segmented on the basis of drug class and type of disease.

On the basis of drug class, it is segmented into acid neutralizers, laxatives & antidiarrheal, antiemetics, antiulcer, and others.

On the basis of type of disease, it is segmented into esophagus diseases, stomach diseases, intestinal diseases, rectum diseases, and others.

MARKET DYNAMICS

1 Introduction

2 Drivers

2.1 Increasing Prevalence Of Gastrointestinal Diseases

2.2 Increasing Investments And Funding In The Field Of Life Science Research

2.3 Increasing Awareness Among The People

2.4 Growing Geriatric Population

2.5 Changing Reimbursement Policies

3 Restraints

3.1 Presence Of Misbranded And Spurious Drugs

4 Opportunities

4.1 Development Of New Drugs

Browse Complete Premium Research Details@ https://www.marketresearchfuture.com/reports/asia-pacific-gastrointestinal-drugs-market-633

To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

To provide country level analysis of the market with respect to the current market size and future prospective

To provide country level analysis of the market for segments by drug class, and its sub-segments.

To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Contraceptive Pills market.

Pfizer Inc. has introduced SAYANA, first injectable contraceptive in UK which can be self-administered.

Teva Pharmaceutical Industries Ltd. has launched Beyaz which is a generic contraceptive drug. It is one of the most successful product of the company and in 2016 it has annual sales of approximately $133 million in the US.

Get an Amazing Discount@ https://www.marketresearchfuture.com/check-discount/2122

INTENDED AUDIENCE

  • Contraceptive pills suppliers
  • Contraceptive pill manufacturers
  • Pharmaceutical Companies
  • Research and Development (R&D) Companies
  • Government Research Laboratories
  • Government and Independent Regulatory Authorities
  • Medical Research Institutes

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/asia-pacific-gastrointestinal-drugs-market-633